BDTX · Black Diamond Therapeutics Inc.
AI read · Good for BDTX
The AI's read
The patient results suggest silevertinib may help people with these lung cancer mutations, including patients with untreated brain metastases. FDA support gives Black Diamond a clearer path to test the drug, but the Phase 3 trial is not planned to start until the second quarter of 2027. Cash fell from $128.7 million at year-end 2025 to $102.0 million in the third quarter, and the company spent $8.3 million operating the business that quarter. The promising results and FDA support outweigh those timing and cash concerns.